Bristol Myers Squibb Selects ZS To Support Global Commercialization and Analytics Capabilities
Global professional services firm ZS has been selected by leading biopharmaceutical company Bristol Myers Squibb (BMS) (NYSE: BMY) to support its worldwide commercial analytics organization. This agreement builds on and expands the existing, successful partnership that BMS and ZS created in 2015.
“We look forward to continuing to serve BMS. It is an honor to help one of the most innovative biopharmaceutical companies in the world transform its analytics capabilities and drive business impact.” said Jaideep Bajaj, chairman of ZS.
The work will support BMS’s Business Insights & Analytics (BIA) group—a global, centralized organization that helps drive business success for all markets and business units across BMS through the appropriate use of data. The scope encompasses areas such as data science, marketing mix, forecasting, business development and brand analytics for more than 65 markets.
“For more than 30 years, BMS and ZS have worked together to solve business challenges and deliver organization-wide impact,” said Rohan Fernando, ZS’s client service lead for BMS. “We are thrilled to continue that partnership and help BMS innovate and drive fact-based decision-making that ultimately helps improve patient outcomes.”
About ZS
ZS is a professional services firm that works side by side with companies to help develop and deliver products that drive customer value and company results. We leverage our deep industry expertise, leading-edge analytics, technology and strategy to create solutions that work in the real world. With more than 35 years of experience and 10,000-plus ZSers in more than 25 offices worldwide, we are passionately committed to helping companies and their customers thrive. To learn more, visit www.zs.com or follow us on Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005033/en/
Contact information
Quintin Maidment
The Bliss Group
ZS@TheBlissGrp.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rimini Street Earns Four 2024 Top Rated Awards from TrustRadius in the Services Category8.5.2024 22:30:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products and services, the leading third-party support provider for Oracle and SAP software, and a Salesforce and AWS partner, today announced that TrustRadius has recognized Rimini Street with four 2024 Top Rated Awards. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508162325/en/ Rimini Street Earns Four 2024 Top Rated Awards from TrustRadius in the Services Category (Graphic: Business Wire) With a strong score of 9 out of 10 based on verified customer reviews, Rimini Street is recognized as a standout in the Product Implementation Services software category. Complementing this primary category, the company was top rated in additional categories, including Consulting and Advisory Services, IT Professional Services, and Managed IT Services. Since 2016, the TrustRadius Top Rated Awards have become the B2B’s industry standard f
Boomi Doubles Down on API Management with Key Acquisitions8.5.2024 18:00:00 CEST | Press release
Boomi™, the intelligent integration and automation leader, today announced the acquisitions of APIIDA’s federated API management business and API management assets from Cloud Software Group, allowing enterprises to rapidly and securely deliver business value through API products in one end-to-end platform. Both these acquisitions accelerate Boomi’s roadmap for providing solutions to the most pressing API management challenges that companies face today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508324428/en/ Boomi Doubles Down on API Management with Key Acquisitions (Graphic: Business Wire) “APIs are the backbone of modern software and application development, and have become a cornerstone of modern architectures that enable businesses to stay agile and compete effectively,” said Steve Lucas, CEO at Boomi. “However, cloud adoption and the explosive growth of APIs have disrupted traditional IT infrastructures. With the
Boomi Unveils New Vision with Strategic Acquisitions and Latest Innovations at Boomi World 20248.5.2024 18:00:00 CEST | Press release
Boomi™, the intelligent integration and automation leader, today unveiled its vision for the company’s future, along with strategic acquisitions and key product announcements at Boomi World 2024. With more than 20,000 global customers and a network of approximately 800 partners worldwide, Boomi is leading the industry towards the future with a focus on integration and automation, API management, and data management, all made more important and powerful than ever with the emergence of the AI economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240508488304/en/ Boomi Unveils New Vision with Strategic Acquisitions and Latest Innovations at Boomi World 2024 (Graphic: Business Wire) In his keynote, Boomi CEO Steve Lucas emphasized the transformative impact of integration platform as a service (iPaaS), spotlighting its pivotal role in enhancing speed, agility, and effectiveness across business operations. Lucas explained how Bo
The smarter E AWARD 2024: Finalists Present Pioneering Solutions for a Renewable 24/7 Energy Supply8.5.2024 17:39:00 CEST | Press release
The energy industry is undergoing a radical transformation. Renewable sources of energy have become increasingly profitable in recent years and are now the most economically viable solution for generating electricity. Deployment is accelerating and the technologies are becoming increasingly sophisticated. This has put renewables in the fast lane. Visionary companies are contributing to this development with modern technologies, ideas and concepts. The best and most innovative developments have been nominated for The smarter E AWARD 2024. The prize is awarded in five categories: Photovoltaics, Energy Storage, E-Mobility, Smart Integrated Energy and Outstanding Projects. The winners will be honored on the eve of The smarter E Europe on June 18 at 6:15pm at the International Congress Center München (ICM). Europe’s largest alliance of exhibitions for the energy industry unites four exhibitions (Intersolar Europe, ees Europe, Power2Drive Europe and EM-Power Europe) and will take place at Me
Study Suggests Critical Link Between Residual FLT3 -ITD Mutations in Remission and Post-Transplant Outcomes in AML8.5.2024 16:00:00 CEST | Press release
A groundbreaking research study,1 sequencing DNA samples from the Pre-MEASURE study2 strongly indicates that the detection of residual FLT3 internal tandem duplication (ITD) mutations in the blood of adult subjects with acute myeloid leukemia (AML) in first complete remission (CR) is associated with worse outcomes after post allogeneic hematopoietic cell transplant (HCT). This follow-up study performed measurable residual disease (MRD) testing on DNA of 537 subjects with FLT3-ITD AML from the Pre-MEASURE study using Invivoscribe’s RUO FLT3 ITD MRD Assay kit and bioinformatics software. Its findings underscore the likely significance of residual FLT3-ITD in first CR in predicting relapse and mortality post-transplant. A key finding from this research study was that AML subjects with residual FLT3-ITD detected prior to allogeneic HCT trended towards elevated risk of relapse and mortality post-transplant, with a dose-dependent correlation within this study population. Dr. Hourigan, Direct